Helene Karcher, Phil Lowe Harnessing clinical knowledge on ligand-targeting drug to develop a new compound targeting the associated receptor : an example of model-based biologics design in pre-clinical development
|
W. Krzyzanski (1), P. Kawczak (1), P. Wiczling (2), P. Lowe (3), E. Pigeolet (3), F. Ludicke (4), S. Balser (4). Receptor Mediated Disposition PK/PD Model of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations.
|
Leonid Gibiansky (1), Tarundeep Kakkar (2), Peiming Ma (2) Population Pharmacokinetics of AMG 317, a Fully Human Anti-IL-4Rα IgG2 Monoclonal Antibody Evaluated in Healthy and Asthmatic Subjects
|
E. Pigeolet (1), P. Wiczling (3), P. Lowe (1), S. Balser (2), A. Berghout (2) and W. Krzyzanski (4) Artefactual inflation of pharmacokinetic difference between two Granulocyte Colony Stimulating Factor (G-CSF) drug products by non compartmental analysis.
|
Rujia Xie1, Rosalin Arends2, Stephen Olson2 , and Scott Marshall1 Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of the Effect of Tanezumab on Overall Daily Pain Score Data in Adults with Moderate-to-Severe Pain due to Osteoarthritis of the Knee
|
Brigitte D. Lacroix(1,2), Mark Lovern(1), Armel Stockis(1), Maria Laura Sargentini-Maier(1), Mats O. Karlsson(2) and Lena E. Friberg(2) Exposure-Response Modeling of the ACR50 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.
|
Stacey Tannenbaum[1], Abhijit Chakraborty[1], Christiane Rordorf[2], Aurélie Gautier[2] & Philip Lowe[2] Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndromes
|
Stacey Tannenbaum[2], Aurelie Gautier[1] & Philip Lowe[1] Relationship between omalizumab pharmacokinetics and IgE pharmacodynamics in adult and pediatric patients with moderate to severe persistent allergic (IgE-mediated) asthma
|
Philip Lowe, Aurelie Gautier On the ability to predict free ligand suppression when free ligand assays are not available or impossible
|
Philip Lowe[1], Stacey Tannenbaum[2], Aurelie Gautier[1] Omalizumab (Xolair) may normalise IgE production rate in patients with moderate-to-severe atopic asthma
|
E. Rouits, M. Lovern, M.L. Sargentini-Maier Target-Mediated Drug Disposition Model to Describe Non-linear Kinetics of a Monoclonal Antibody
|